These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30057378)

  • 1. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19-9 and CEA.
    Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
    Pol Arch Intern Med; 2018 Sep; 128(9):524-531. PubMed ID: 30057378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific Receptors for the Chemokines CXCR2 and CXCR4 in Pancreatic Cancer.
    Litman-Zawadzka A; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Kędra B; Mroczko B
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations of receptor for interleukin 8 in patients with esophageal cancer.
    Łukaszewicz-Zając M; Kulczyńska-Przybik A; Muszyński P; Kozłowski M; Szmitkowski M; Mroczko B
    Pol Arch Med Wewn; 2016 Oct; 126(11):854-861. PubMed ID: 27906878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.
    Lukaszewicz-Zając M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
    Clin Exp Med; 2011 Jun; 11(2):89-96. PubMed ID: 20938721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
    Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
    J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
    Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
    Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Utility of Serum CXCR-2 Assessment in Colorectal Cancer (CRC) Patients.
    Pączek S; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
    Anticancer Res; 2021 Mar; 41(3):1421-1428. PubMed ID: 33788733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.
    Lee JH
    Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients.
    Łukaszewicz-Zając M; Mroczko B; Kozłowski M; Nikliński J; Laudański J; Szmitkowski M
    Dis Esophagus; 2012 Apr; 25(3):242-9. PubMed ID: 21895853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL-8 in Preoperative Colorectal Cancer Patients: Significance for Diagnosis and Cancer Progression.
    Pączek S; Łukaszewicz-Zając M; Gryko M; Mroczko P; Kulczyńska-Przybik A; Mroczko B
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192002
    [No Abstract]   [Full Text] [Related]  

  • 16. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
    Zhang SY; Lin M; Zhang HB
    Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.